1477 Results

People

  1. Motzer
    Motzer
  2. Hudis
    Hudis
  3. Aghajanian
    Aghajanian
  4. O'Reilly
    O'Reilly
  5. Kris
    Kris
  6. Scher
    Scher
  7. Panageas
    Panageas
  8. Saltz
    Saltz
  9. Schwartz
    Schwartz
  10. Kelsen
    Kelsen

Groups

  1. Department of Medicine (1039)
  2. Solid Tumor Oncology Division (784)
  3. Hematologic Malignancies, Division of (287)
  4. Survivorship Research (234)
  5. Center for Hematologic Malignancies (216)
  6. Genitourinary Oncology Service (208)
  7. Epidemiology and Biostatistics (194)
  8. Biostatistics Service (169)
  9. Gastrointestinal Oncology Service (160)
  10. Population Sciences Research Program (158)
  1. "fatigue"
Formats
  1. Journal Article (1402)
  2. Review (38)
  3. Research Letter (13)
  4. Editorial (10)
  5. Conference Paper (5)
  6. Guidelines (4)
  7. Correspondence (3)
  8. Book Section (2)
Groups
  1. Department of Medicine (1039)
  2. Solid Tumor Oncology Division (784)
  3. Hematologic Malignancies, Division of (287)
  4. Survivorship Research (234)
  5. Center for Hematologic Malignancies (216)
  6. Genitourinary Oncology Service (208)

More Groups

People
  1. Robert Motzer (85)
  2. Clifford Hudis (49)
  3. Carol Aghajanian (46)
  4. Eileen O'Reilly (46)
  5. Howard Scher (44)
  6. Mark Kris (44)

More People

Years
  1. 2025 (60)
  2. 2024 (132)
  3. 2023 (89)
  4. 2022 (46)
  5. 2021 (33)
  6. 2020 (85)

More Years

Publications
  1. Journal of Clinical Oncology (108)
  2. Clinical Cancer Research (82)
  3. Cancer (63)
  4. Lancet Oncology (50)
  5. Gynecologic Oncology (41)
  6. Annals of Oncology (37)

More Publications

Publishers
  1. Elsevier Inc. (244)
  2. Springer (133)
  3. American Society of Clinical Oncology (114)
  4. Elsevier Science, Inc. (108)
  5. Oxford University Press (101)
  6. American Association for Cancer Research (89)

More Publishers

Results (1477)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Pembrolizumab alone and pembrolizumab plus chemotherapy in previously treated, extrapulmonary poorly differentiated neuroendocrine carcinomas
    Journal Article

    Raj, N.; Chan, J. A.; Wang, S. J.; Aggarwal, R. R.; Calabrese, S.; DeMore, A.; Fong, L.; Grabowsky, J.; Hope, T. A.; Kolli, K. P.; more...
    British Journal of Cancer (2023)

    Fulltext@MSK | Save
  • Validating the PROMIS cognitive function short form in cancer survivors
    Journal Article

    Henneghan, A. M.; Van Dyk, K.; Zhou, X.; Moore, R. C.; Root, J. C.; Ahles, T. A.; Nakamura, Z. M.; Mandeblatt, J.; Ganz, P. A.
    Breast Cancer Research and Treatment (2023)

    Fulltext@MSK | Save
  • A platform trial of neoadjuvant and adjuvant antitumor vaccination alone or in combination with PD-1 antagonist and CD137 agonist antibodies in patients with resectable pancreatic adenocarcinoma
    Journal Article

    Heumann, T.; Judkins, C.; Li, K.; Lim, S. J.; Hoare, J.; Parkinson, R.; Cao, H.; Zhang, T.; Gai, J.; Celiker, B.; more...
    Nature Communications (2023)

    Fulltext@MSK | Save
  • Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer
    Review

    Rudin, C. M.; Reck, M.; Johnson, M. L.; Blackhall, F.; Hann, C. L.; Yang, J. C. H.; Bailis, J. M.; Bebb, G.; Goldrick, A.; Umejiego, J.; more...
    Journal of Hematology & Oncology (2023)

    Fulltext@MSK | Save
  • A phase 2 study of dasatinib in recurrent clear cell carcinoma of the ovary, fallopian tube, peritoneum or endometrium: NRG Oncology/Gynecologic Oncology Group study 0283
    Journal Article

    O'Cearbhaill, R. E.; Miller, A.; Soslow, R. A.; Lankes, H. A.; DeLair, D.; Segura, S.; Chavan, S.; Zamarin, D.; DeBernardo, R.; Moore, K.; more...
    Gynecologic Oncology (2023)

    Fulltext@MSK | Save
  • Patient-reported symptoms after minimally invasive hysterectomy and association with postoperative complications
    Journal Article

    Feinberg, J.; Zivanovic, O.; Hannon, M.; McCready, T.; Desai, P.; Kim, S. H.; Aviki, E. M.; Mueller, J. J.; Jewell, E. L.; Roche, K. L.; more...
    Gynecologic Oncology (2023)

    Fulltext@MSK | Save
  • Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results
    Journal Article

    Mauro, M. J.; Hughes, T. P.; Kim, D. W.; Rea, D.; Cortes, J. E.; Hochhaus, A.; Sasaki, K.; Breccia, M.; Talpaz, M.; Ottmann, O.; more...
    Leukemia (2023)

    Fulltext@MSK | Save
  • Patient-reported fatigue and pain in Erdheim-Chester disease: A registry-based, mixed methods study
    Research Letter

    Reiner, A. S.; Bossert, D.; Buthorn, J. J.; Sigler, A. M.; Gonen, S.; Fournier, D.; Brewer, K.; Corkran, J.; Goyal, G.; Allen, C. E.; more...
    Haematologica (2023)

    Fulltext@MSK | Save
  • Targeting RARA overexpression with tamibarotene, a potent and selective RARα agonist, is a novel approach in AML
    Journal Article

    de Botton, S.; Cluzeau, T.; Vigil, C.; Cook, R. J.; Rousselot, P.; Rizzieri, D. A.; Liesveld, J. L.; Fenaux, P.; Braun, T.; Banos, A.; more...
    Blood Advances (2023)

    Fulltext@MSK | Save
  • A phase II single-arm trial of memantine for prevention of cognitive decline during chemotherapy in patients with early breast cancer: Feasibility, tolerability, acceptability, and preliminary effects
    Journal Article

    Nakamura, Z. M.; Deal, A. M.; Park, E. M.; Stanton, K. E.; Lopez, Y. E.; Quillen, L. J.; O’Hare Kelly, E.; Heiling, H. M.; Nyrop, K. A.; Ray, E. M.; more...
    Cancer Medicine (2023)

    Fulltext@MSK | Save